Stevanato Group S.p.A. (STVN) company profile
Close on Nov 17, 2026Market cap $4.62BP/E 27.1Yield –
About Stevanato Group S.p.A.
Surgical & Medical Instruments & Apparatus, SIC 3841
Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions, alongside manufacturing engineering systems for the pharmaceutical, biotechnology, and life sciences industries. It operates through two primary segments: Biopharmaceutical and Diagnostic Solutions, which supplies products such as pre-fillable syringes, vials, cartridges, diagnostic consumables, and drug delivery devices; and Engineering, which designs visual inspection, assembly, packaging, and serialization machinery. The company primarily serves global pharmaceutical, biotechnology, and diagnostic businesses, supporting their drug product life cycles from research through commercial production.
Headquartered in Piombino Dese (Padua), Italy, the company distributes its products and services across approximately 65 countries worldwide. Its global infrastructure includes 13 manufacturing plants, comprising ten production facilities for biopharmaceutical and healthcare products and three plants dedicated to equipment and machinery, located in Italy, Germany, Slovakia, Brazil, Mexico, China, Denmark, and the United States. In addition, the firm maintains two analytical testing sites and five commercial offices globally.
Summary of the business section of Stevanato Group S.p.A.'s latest annual report, written by StockData.
Company profile
Company
- Legal name
- Stevanato Group S.p.A.
- Founded
- 1949
- Headquarters
- Padua, Italy
- Address
- Piombino Dese (Pd) Via Molinella, 17 35017
- Phone
- 39 049 9318173
- Website
- stevanatogroup.com
- Employees
- 6,010, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Auditor
- PricewaterhouseCoopers SpA, Treviso, Italy
Stock & identifiers
- Ticker
- STVN
- Exchange
- NYSE
- IPO date
- Jul 16, 2021
- Shares outstanding
- 303M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1849853
- CUSIP
- T9224W109
- FIGI
- BBG001RY95L9
- Share class FIGI
- BBG001V2NPF1
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Franco Stevanato | Chief Executive Officer, Director | – |
| Mauro Stocchi | See Remarks | 400,000 |
| Lago Marco Dal | Chief Financial Officer | 81,144 |
| William J. Federici | Director | 78,580 |
| Donald E. Morel Jr | Director | 62,424 |
| Elisabetta Magistretti | Director | 2,930 |
| Luciano Santel | Director | 4,739 |
| Karen Flynn | Director | 5,757 |
| Madhavan Balachandran | Director | 69,458 |
| Sue-Jean Lin | Director | 6,975 |
| Alvise Spinazzi | Director | 3,300 |
| Fabrizio Bonanni | Director | 119,700 |
| Sergio Stevanato | Director | 253,238,887 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 16, 2021
- Offer price
- $21.00
- Exchange
- NYSE
- First trading day
- Jul 16, 2021
- First-day close
- $19.67-6.3%
- Lock-up ends (est.)
- Jan 12, 2022
“The initial public offering price is $21.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 6,010 employees in multiple jurisdictions (approximately 58% based in Italy, 10% based in Germany, 8% based in the U.S., 7% based in Mexico, 5% based in Brazil, 4% based in each Slovakia, and Denmark, and 3% based in China).”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 16, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 15, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?